diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13043diaendo-13043Research ArticleОбзорыReviewОбзор современных датчиков для непрерывного мониторирования уровня глюкозыOverview of modern sensors for continuous glucose monitoringhttps://orcid.org/0000-0003-4656-1025МомыналиевК. Т.MomynalievK. T.

Момыналиев Куват Темиргалиевич, д.б.н., доцент 

Scopus Author ID: 6603847759

115478, г. Москва, Каширское ш., д. 24, стр. 16 

Kuvat T. Momynaliev, PhD in Biology, Associate Professor 

Scopus Author ID: 6603847759

16/24 Kashirskoye sh., 115478 Moscow

kmomynaliev@vniiimt.ruПрокопьевМ. В.ProkopievM. V.

Прокопьев Максим Владимирович, к.м.н. 

Maxim V. Prokopiev, PhD 

Moscow

 

mprokopev@vniiimt.ruhttps://orcid.org/0000-0003-0971-853XИвановИ. В.IvanovI. V.

Игорь Владимирович Иванов, д.м.н. 

Igor V. Ivanov, PhD

Moscow

ivanov@vniiimt.ruВсероссийский научно-исследовательский и испытательный институт медицинской техникиРоссияAll-Russian Scientific, Research and Testing Institute for Medical DevicesRussian Federation202325092023266575584Copyright © Момыналиев К.Т., Прокопьев М.В., Иванов И.В., 20232023Момыналиев К.Т., Прокопьев М.В., Иванов И.В.Momynaliev K.T., Prokopiev M.V., Ivanov I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13043

Заболеваемость сахарным диабетом (СД) увеличивается во всех возрастных группах. Использование технологических устройств для лечения СД, таких как системы непрерывного мониторинга глюкозы (СНМГ), расширяется и связано с улучшением контроля уровня глюкозы с целью предотвращения осложнений этого заболевания. Снижение гликемической вариабельности и поддержание оптимального гликемического контроля имеет решающее значение для лечения пациентов с СД 1 типа. Полезность устройств для мониторинга гликемии также была показана для пациентов с СД 2 типа. Технология непрерывного мониторинга глюкозы (НМГ) постоянно совершенствуется с точки зрения аналитических характеристик, биосовместимости, продолжительности ношения, безопасности и клинических характеристик. Однако широко распространенные минимально инвазивные СНМГ измеряют не уровень глюкозы в крови напрямую, а концентрацию глюкозы в интерстициальной жидкости (ИСЖ), поэтому изменения уровня глюкозы в ИСЖ происходят с опозданием 5–15 мин по сравнению с уровнем глюкозы в крови. Кроме того, срок жизни датчиков минимально инвазивных СНМГ относительно короткий, до 14 дней. Поэтому внедрение в клиническую практику изделий для неинвазивного измерения уровня глюкозы у людей с СД, которые преодолеют указанные выше ограничения минимально инвазивных СНМГ, позволит расширить возможности мониторинга глюкозы среди пациентов с СД. Целью данного обзора было представить технологии датчиков СНМГ, разрешенных для использования в медицинских целях в России и других странах.

The incidence of diabetes is increasing in all age groups. The use of technological devices for the treatment of diabetes, such as continuous glucose monitoring (CGM), is expanding and is associated with improved control of blood glucose levels in order to prevent complications of this disease. Reducing glycemic variability and maintaining optimal glycemic control is critical to the management of patients with type 1 diabetes. The usefulness of glycemic monitoring devices has also been shown for patients with type 2 diabetes. CGM technology is constantly being improved in terms of analytical performance, biocompatibility, wear duration, safety and clinical performance. However, commonly used minimally invasive CGMs do not measure blood glucose directly, but instead measure the glucose concentration in the interstitial fluid (IF), so changes in IF glucose occur with a delay of 5 to 15 minutes compared to blood glucose. In addition, the lifetime of minimally invasive CGM sensors is relatively short, up to 14 days. Therefore, the introduction into clinical practice of devices for non-invasive glucose measurement in people with diabetes, which overcome the above-mentioned limitations of minimally invasive CGM, will expand the possibilities of glucose monitoring among patients with diabetes. The purpose of this review was to present the technologies of CGM system sensors approved for medical use in Russia and other countries.

сахарный диабетнепрерывный мониторинг глюкозыдатчикмедицинское изделиерегистрацияdiabetes mellituscontinuous glucose monitoringsensormedical deviceregistrationReferencesInternational Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2022 [cited 29.11.2023]. Available from: https://diabetesatlas.org/atlas/tenth-edition/International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2022 [cited 29.11.2023]. Available from: https://diabetesatlas.org/atlas/tenth-edition/Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010 -2022 гг // Сахарный диабет. — 2023. — Т. 26. — №2. — С. 104-123. doi: https://doi.org/10.14341/DM13035Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010 -2022. Diabetes Mellitus. 2023;26(2):104-123. (In Russ.). doi: https://doi.org/10.14341/DM13035Российская ассоциация эндокринологов. Клинические рекомендации. Сахарный диабет 2 типа у взрослых. М.: Министерство здравоохранения РФ; 2022.Доступно по: https://cr.minzdrav.gov.ru/schema/290_2. Ссылка активна на 29.11.2023.Rossijskaja associacija jendokrinologov. Klinicheskie rekomendacii. Saharnyj diabet 2 tipa u vzroslyh. Moscow: Ministerstvo zdravoohranenija RF; 2022. (In Russ.). URL: https://cr.minzdrav.gov.ru/schema/290_2. 29.11.2023.Beck RW, Bergenstal RM, Laffel LM, Pickup JC. Advances in technology for management of type 1 diabetes. Lancet. 2019;394(10205):1265-1273. doi: https://doi.org/10.1016/S0140-6736(19)31142-0Beck RW, Bergenstal RM, Laffel LM, Pickup JC. Advances in technology for management of type 1 diabetes. Lancet. 2019;394(10205):1265-1273. doi: https://doi.org/10.1016/S0140-6736(19)31142-0DeSalvo DJ, Miller KM, Hermann JM, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes. 2018;19(7):1271-1275. doi: https://doi.org/10.1111/pedi.12711DeSalvo DJ, Miller KM, Hermann JM, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes. 2018;19(7):1271-1275. doi: https://doi.org/10.1111/pedi.12711Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018 [published correction appears in Diabetes Technol Ther. 2019;21(4):230]. Diabetes Technol Ther. 2019;21(2):66-72. doi: https://doi.org/10.1089/dia.2018.0384Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018 [published correction appears in Diabetes Technol Ther. 2019;21(4):230]. Diabetes Technol Ther. 2019;21(2):66-72. doi: https://doi.org/10.1089/dia.2018.0384Cardona-Hernandez R, Schwandt A, Alkandari H, et al. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the International Pediatric Registry SWEET. Diabetes Care. 2021;44(5):1176-1184. doi: https://doi.org/10.2337/dc20-1674Cardona-Hernandez R, Schwandt A, Alkandari H, et al. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the International Pediatric Registry SWEET. Diabetes Care. 2021;44(5):1176-1184. doi: https://doi.org/10.2337/dc20-1674Pauley ME, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous glucose monitor, insulin pump, and automated insulin delivery therapies for type 1 diabetes: An update on potential for cardiovascular benefits. Curr Cardiol Rep. 2022;24(12):2043-2056. doi: https://doi.org/10.1007/s11886-022-01799-xPauley ME, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous glucose monitor, insulin pump, and automated insulin delivery therapies for type 1 diabetes: An update on potential for cardiovascular benefits. Curr Cardiol Rep. 2022;24(12):2043-2056. doi: https://doi.org/10.1007/s11886-022-01799-xBruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab Res Rev. 2009;25(2):99-111. doi: https://doi.org/10.1002/dmrr.931Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab Res Rev. 2009;25(2):99-111. doi: https://doi.org/10.1002/dmrr.931Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: A randomized clinical trial. JAMA. 2020;323(23):2388-2396. doi: https://doi.org/10.1001/jama.2020.6940Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: A randomized clinical trial. JAMA. 2020;323(23):2388-2396. doi: https://doi.org/10.1001/jama.2020.6940Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017;8(4):947-951. doi: https://doi.org/10.1007/s13300-017-0281-4Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017;8(4):947-951. doi: https://doi.org/10.1007/s13300-017-0281-4Irace C, Cutruzzolà A, Nuzzi A, et al. Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(7):1056-1061. doi: https://doi.org/10.1111/dom.13993Irace C, Cutruzzolà A, Nuzzi A, et al. Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(7):1056-1061. doi: https://doi.org/10.1111/dom.13993Российская ассоциация эндокринологов. Клинические рекомендации. Сахарный диабет 1 типа у взрослых. М.: Министерство здравоохранения РФ; 2022. Доступно по: https://cr.minzdrav.gov.ru/schema/286_2. Ссылка активна на 29.11.2023.Rossijskaja associacija jendokrinologov. Klinicheskie rekomendacii. Saharnyj diabet 1 tipa u vzroslyh. Moscow: Ministerstvo zdravoohranenija RF; 2022. (In Russ.). URL: https://cr.minzdrav.gov.ru/schema/286_2. СChen C, Zhao XL, Li ZH, et al. Current and emerging technology for continuous glucose monitoring. Sensors (Basel). 2017;17(1):182. doi: https://doi.org/10.3390/s17010182Chen C, Zhao XL, Li ZH, et al. Current and emerging technology for continuous glucose monitoring. Sensors (Basel). 2017;17(1):182. doi: https://doi.org/10.3390/s17010182Schmelzeisen-Redeker G, Schoemaker M, Kirchsteiger H, et al. Time delay of CGM Sensors: relevance, causes, and countermeasures. J Diabetes Sci Technol. 2015;9(5):1006-1015. doi: https://doi.org/10.1177/1932296815590154Schmelzeisen-Redeker G, Schoemaker M, Kirchsteiger H, et al. Time delay of CGM Sensors: relevance, causes, and countermeasures. J Diabetes Sci Technol. 2015;9(5):1006-1015. doi: https://doi.org/10.1177/1932296815590154Bailey T, Bode BW, Christiansen MP, et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787-794. doi: https://doi.org/10.1089/dia.2014.0378Bailey T, Bode BW, Christiansen MP, et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787-794. doi: https://doi.org/10.1089/dia.2014.0378Bailey TS, Chang A, Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol. 2015;9(2):209-214. doi: https://doi.org/10.1177/1932296814559746Bailey TS, Chang A, Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol. 2015;9(2):209-214. doi: https://doi.org/10.1177/1932296814559746Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabetes Technol Ther. 2000;2(3):461-472. doi: https://doi.org/10.1089/15209150050194332Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabetes Technol Ther. 2000;2(3):461-472. doi: https://doi.org/10.1089/15209150050194332Wang J. Electrochemical glucose biosensors. Chem Rev. 2008;108(2):814-825. doi: https://doi.org/10.1021/cr068123aWang J. Electrochemical glucose biosensors. Chem Rev. 2008;108(2):814-825. doi: https://doi.org/10.1021/cr068123aKavanagh P, Leech D. Mediated electron transfer in glucose oxidising enzyme electrodes for application to biofuel cells: recent progress and perspectives. Phys Chem Chem Phys. 2013;15(14):4859-4869. doi: https://doi.org/10.1039/c3cp44617dKavanagh P, Leech D. Mediated electron transfer in glucose oxidising enzyme electrodes for application to biofuel cells: recent progress and perspectives. Phys Chem Chem Phys. 2013;15(14):4859-4869. doi: https://doi.org/10.1039/c3cp44617dWongkaew N, Simsek M, Griesche C, Baeumner AJ. Functional nanomaterials and nanostructures enhancing electrochemical biosensors and Lab-on-a-Chip performances: recent progress, applications, and future perspective. Chem Rev. 2019;119(1):120-194. doi: https://doi.org/10.1021/acs.chemrev.8b00172Wongkaew N, Simsek M, Griesche C, Baeumner AJ. Functional nanomaterials and nanostructures enhancing electrochemical biosensors and Lab-on-a-Chip performances: recent progress, applications, and future perspective. Chem Rev. 2019;119(1):120-194. doi: https://doi.org/10.1021/acs.chemrev.8b00172Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous glucose monitoring sensors for diabetes management: A review of technologies and applications. Diabetes Metab J. 2019;43(4):383-397. doi: https://doi.org/10.4093/dmj.2019.0121Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous glucose monitoring sensors for diabetes management: A review of technologies and applications. Diabetes Metab J. 2019;43(4):383-397. doi: https://doi.org/10.4093/dmj.2019.0121Almurashi AM, Rodriguez E, Garg SK. Emerging diabetes technologies: continuous glucose monitors/artifi pancreases. J Indian Inst Sci. 2023;103(1):205-230. doi: https://doi.org/10.1007/s41745-022-00348-3Almurashi AM, Rodriguez E, Garg SK. Emerging diabetes technologies: continuous glucose monitors/artifi pancreases. J Indian Inst Sci. 2023;103(1):205-230. doi: https://doi.org/10.1007/s41745-022-00348-3Feldman B, McGarraugh G, Heller A, et al. FreeStyle: a smallvolume electrochemical glucose sensor for home blood glucose testing. Diabetes Technol Ther. 2000;2(2):221-229. doi: https://doi.org/10.1089/15209150050025177Feldman B, McGarraugh G, Heller A, et al. FreeStyle: a smallvolume electrochemical glucose sensor for home blood glucose testing. Diabetes Technol Ther. 2000;2(2):221-229. doi: https://doi.org/10.1089/15209150050025177Ungerstedt U, Pycock C. Functional correlates of dopamine neurotransmission. Bull Schweiz Akad Med Wiss. 1974;30(1-3):44-55.Ungerstedt U, Pycock C. Functional correlates of dopamine neurotransmission. Bull Schweiz Akad Med Wiss. 1974;30(1-3):44-55.Valgimigli F, Lucarelli F, Scuffi C, et al. Evaluating the clinical accuracy of GlucoMen®Day: A novel microdialysis-based continuous glucose monitor. J Diabetes Sci Technol. 2010;4(5):1182-1192. doi: https://doi.org/10.1177/193229681000400517Valgimigli F, Lucarelli F, Scuffi C, et al. Evaluating the clinical accuracy of GlucoMen®Day: A novel microdialysis-based continuous glucose monitor. J Diabetes Sci Technol. 2010;4(5):1182-1192. doi: https://doi.org/10.1177/193229681000400517WaveForm Diabetes (formerly Agamatrix), Bayer CGM. Desang diabetes services. June 16, 2020 [cited 15.12.2020]. Available from: https://www.desang.net/2020/06/waveform-diabetes-formerly-agamatrix-and-bayer-cgm/WaveForm Diabetes (formerly Agamatrix), Bayer CGM. Desang diabetes services. June 16, 2020 [cited 15.12.2020]. Available from: https://www.desang.net/2020/06/waveform-diabetes-formerly-agamatrix-and-bayer-cgm/Hochfellner DA, Simic A, Taucher MT, et al. Accuracy Assessment of the GlucoMen® Day CGM system in individuals with type 1 diabetes: A pilot study. Biosensors (Basel). 2022;12(2):106. doi: https://doi.org/10.3390/bios12020106Hochfellner DA, Simic A, Taucher MT, et al. Accuracy Assessment of the GlucoMen® Day CGM system in individuals with type 1 diabetes: A pilot study. Biosensors (Basel). 2022;12(2):106. doi: https://doi.org/10.3390/bios12020106Jernelv IL, Milenko K, Fuglerud SS, et al. A review of optical methods for continuous glucose monitoring. Appl Spectrosc Rev. 2019;54(7):543-572. doi: https://doi.org/10.1080/05704928.2018.1486324Jernelv IL, Milenko K, Fuglerud SS, et al. A review of optical methods for continuous glucose monitoring. Appl Spectrosc Rev. 2019;54(7):543-572. doi: https://doi.org/10.1080/05704928.2018.1486324Kocheril PA, Lenz KD, Mukundan H. Total internal reflection of two lasers in a single planar optical waveguide. ECS Sensors Plus. 2022;1(2):021601. doi: https://doi.org/10.1149/2754-2726/ac6523Kocheril PA, Lenz KD, Mukundan H. Total internal reflection of two lasers in a single planar optical waveguide. ECS Sensors Plus. 2022;1(2):021601. doi: https://doi.org/10.1149/2754-2726/ac6523Eversense Continuous Glucose Monitoring System. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160048B.pdf [cited 29.11.2023].Eversense Continuous Glucose Monitoring System. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160048B.pdf [cited 29.11.2023].Kropff J, Choudhary P, Neupane S, et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: A 180-day, prospective, multicenter, pivotal trial. Diabetes Care. 2017;40(1):63-68. doi: https://doi.org/10.2337/dc16-1525Kropff J, Choudhary P, Neupane S, et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: A 180-day, prospective, multicenter, pivotal trial. Diabetes Care. 2017;40(1):63-68. doi: https://doi.org/10.2337/dc16-1525Christiansen MP, Klaff LJ, Brazg R, et al. A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technol Ther. 2018;20(3):197-206. doi: https://doi.org/10.1089/dia.2017.0142Christiansen MP, Klaff LJ, Brazg R, et al. A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technol Ther. 2018;20(3):197-206. doi: https://doi.org/10.1089/dia.2017.0142Christiansen MP, Klaff LJ, Bailey TS, et al. A prospective multicenter evaluation of the accuracy and safety of an implanted continuous glucose sensor: The PRECISION study. Diabetes Technol Ther. 2019;21(5):231-237. doi: https://doi.org/10.1089/dia.2019.0020Christiansen MP, Klaff LJ, Bailey TS, et al. A prospective multicenter evaluation of the accuracy and safety of an implanted continuous glucose sensor: The PRECISION study. Diabetes Technol Ther. 2019;21(5):231-237. doi: https://doi.org/10.1089/dia.2019.0020Sieg A, Guy RH, Delgado-Charro MB. Noninvasive glucose monitoring by reverse iontophoresis in vivo: application of the internal standard concept. Clin Chem. 2004;50(8):1383-1390. doi: https://doi.org/10.1373/clinchem.2004.032862Sieg A, Guy RH, Delgado-Charro MB. Noninvasive glucose monitoring by reverse iontophoresis in vivo: application of the internal standard concept. Clin Chem. 2004;50(8):1383-1390. doi: https://doi.org/10.1373/clinchem.2004.032862GlucoWatch® G2 Biographer. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/p990026s008b.pdf [cited 29.11.2023].GlucoWatch® G2 Biographer. Available from: https://www.accessdata. fda.gov/cdrh_docs/pdf/p990026s008b.pdf [cited 29.11.2023].Tierney MJ, Tamada JA, Potts RO, et al. Clinical evaluation of the GlucoWatch® biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron. 2001;16(9-12):621-629. doi: https://doi.org/10.1016/S0956-5663(01)00189-0Tierney MJ, Tamada JA, Potts RO, et al. Clinical evaluation of the GlucoWatch® biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron. 2001;16(9-12):621-629. doi: https://doi.org/10.1016/S0956-5663(01)00189-0Potts RO, Tamada JA, Tierney MJ. Glucose monitoring by reverse iontophoresis. Diabetes Metab Res Rev. 2002;189(S1):S49-S53. doi: https://doi.org/10.1002/dmrr.210Potts RO, Tamada JA, Tierney MJ. Glucose monitoring by reverse iontophoresis. Diabetes Metab Res Rev. 2002;189(S1):S49-S53. doi: https://doi.org/10.1002/dmrr.210Caduff A, Dewarrat F, Talary M, et al. Non-invasive glucose monitoring in patients with diabetes: a novel system based on impedance spectroscopy. Biosens Bioelectron. 2006;22(5):598-604. doi: https://doi.org/10.1016/j.bios.2006.01.031Caduff A, Dewarrat F, Talary M, et al. Non-invasive glucose monitoring in patients with diabetes: a novel system based on impedance spectroscopy. Biosens Bioelectron. 2006;22(5):598-604. doi: https://doi.org/10.1016/j.bios.2006.01.031Weinzimer SA. PENDRA: the once and future noninvasive continuous glucose monitoring device? Diabetes Technol Ther. 2004;6(4):442-444. doi: https://doi.org/10.1089/1520915041706018Weinzimer SA. PENDRA: the once and future noninvasive continuous glucose monitoring device? Diabetes Technol Ther. 2004;6(4):442-444. doi: https://doi.org/10.1089/1520915041706018Wentholt IM, Hoekstra JB, Zwart A, DeVries JH. Pendra goes Dutch: lessons for the CE mark in Europe. Diabetologia. 2005;48(6):1055-1058. doi: https://doi.org/10.1007/s00125-005-1754-yWentholt IM, Hoekstra JB, Zwart A, DeVries JH. Pendra goes Dutch: lessons for the CE mark in Europe. Diabetologia. 2005;48(6):1055-1058. doi: https://doi.org/10.1007/s00125-005-1754-yFreckmann G. Basics and use of continuous glucose monitoring (CGM) in diabetes therapy. J Lab Med. 2020;44(2):71-79. doi: https://doi.org/10.1515/labmed-2019-0189Freckmann G. Basics and use of continuous glucose monitoring (CGM) in diabetes therapy. J Lab Med. 2020;44(2):71-79. doi: https://doi.org/10.1515/labmed-2019-0189Witkowska Nery E, Kundys M, Jeleń PS, Jönsson-Niedziółka M. Electrochemical glucose sensing: Is there still room for improvement? Anal Chem. 2016;88(23):11271-11282. doi: https://doi.org/10.1021/acs.analchem.6b03151Witkowska Nery E, Kundys M, Jeleń PS, Jönsson-Niedziółka M. Electrochemical glucose sensing: Is there still room for improvement? Anal Chem. 2016;88(23):11271-11282. doi: https://doi.org/10.1021/acs.analchem.6b03151Joseph JI. Review of the long-term implantable senseonics continuous glucose monitoring system and other continuous glucose monitoring systems [published correction appears in J Diabetes Sci Technol. 2021 Dec 14]. J Diabetes Sci Technol. 2021;15(1):167-173. doi: https://doi.org/10.1177/1932296820911919Joseph JI. Review of the long-term implantable senseonics continuous glucose monitoring system and other continuous glucose monitoring systems [published correction appears in J Diabetes Sci Technol. 2021 Dec 14]. J Diabetes Sci Technol. 2021;15(1):167-173. doi: https://doi.org/10.1177/1932296820911919Saraoğlu HM, Koçan M. A study on non‐invasive detection of blood glucose concentration from human palm perspiration by using artificial neural networks. Expert Syst. 2010;27(3):156-165. doi: https://doi.org/10.1111/j.1468-0394.2010.00523.xSaraoğlu HM, Koçan M. A study on non‐invasive detection of blood glucose concentration from human palm perspiration by using artificial neural networks. Expert Syst. 2010;27(3):156-165. doi: https://doi.org/10.1111/j.1468-0394.2010.00523.xDu Y, Zhang W, Wang ML. An on-chip disposable salivary glucose sensor for diabetes control. J Diabetes Sci Technol. 2016;10(6):1344-1352. doi: https://doi.org/10.1177/1932296816642251Du Y, Zhang W, Wang ML. An on-chip disposable salivary glucose sensor for diabetes control. J Diabetes Sci Technol. 2016;10(6):1344-1352. doi: https://doi.org/10.1177/1932296816642251Chakraborty P, Dhar S, Deka N, et al. Non-enzymatic salivary glucose detection using porous CuO nanostructures. Sensors Actuators B Chem. 2020;302:127134. doi: https://doi.org/10.1016/j.snb.2019.127134Chakraborty P, Dhar S, Deka N, et al. Non-enzymatic salivary glucose detection using porous CuO nanostructures. Sensors Actuators B Chem. 2020;302:127134. doi: https://doi.org/10.1016/j.snb.2019.127134Macaya DJ, Nikolou M, Takamatsu S, et al. Simple glucose sensors with micromolar sensitivity based on organic electrochemical transistors. Sensors Actuators B Chem. 2007;123(1):374-378. doi: https://doi.org/10.1016/j.snb.2006.08.038Macaya DJ, Nikolou M, Takamatsu S, et al. Simple glucose sensors with micromolar sensitivity based on organic electrochemical transistors. Sensors Actuators B Chem. 2007;123(1):374-378. doi: https://doi.org/10.1016/j.snb.2006.08.038Available from: https://www.bloomberg.com/news/articles/2023-02-22/apple-watch-blood-glucose-monitor-could- revolutionize-diabetes-care-aap [cited 29.11.2023].Available from: https://www.bloomberg.com/news/articles/2023-02-22/apple-watch-blood-glucose-monitor-could- revolutionize-diabetes-care-aap [cited 29.11.2023].Available from: https://www.pkvitality.com/wp-content/uploads/2022/07/PKvitality-FIH-3-ENG-final.pdf [cited 29.11.2023]Available from: https://www.pkvitality.com/wp-content/uploads/2022/07/PKvitality-FIH-3-ENG-final.pdf [cited 29.11.2023]

The authors declare that there are no conflicts of interest present.